Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice
Alice Nemajerova, Oleksi Petrenko, Lorenz Trümper, Gustavo Palacios, Ute M. Moll
Alice Nemajerova, Oleksi Petrenko, Lorenz Trümper, Gustavo Palacios, Ute M. Moll
View: Text | PDF
Research Article Hematology

Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice

  • Text
  • PDF
Abstract

Mice engineered to express c-Myc in B cells (Eμ-myc mice) develop lethal lymphomas in which the gene encoding the p53 tumor suppressor is frequently mutated. Whether the p53 homolog p73 also functions as a tumor suppressor in vivo remains controversial. Here we have shown that p73 loss does not substantially affect disease onset and mortality in Eμ-myc mice. However, it does alter the phenotype of the disease. Specifically, p73 loss decreased nodal disease and increased widespread extranodal dissemination. We further found that p53 acted as the dominant tumor suppressor during the onset of Eμ-myc–driven B cell lymphomagenesis, while p73 modulated tumor dissemination and extranodal growth. Immunophenotyping and expression profiling suggested that p73 loss allowed increased maturation of malignant B cells and deregulated genes involved in lymphocyte homing and dissemination of human lymphomas. Consistent with this, p73 expression was frequently downregulated in a large cohort of human mature aggressive B cell lymphomas, and both the incidence and degree of p73 downregulation in these tumors correlated with their extranodal dissemination status. These data indicate that p73 is a modifier of Myc-driven lymphomas in mice, favoring tumor dissemination, and suggest that p73 could be a biomarker for human B cell lymphoma dissemination, a notion that can now be tested in clinicopathologic correlation studies.

Authors

Alice Nemajerova, Oleksi Petrenko, Lorenz Trümper, Gustavo Palacios, Ute M. Moll

×

Figure 2

In the context of Myc, the absence of p73 allows increased maturation of premalignant B cells.

Options: View larger image (or click on image) Download as PowerPoint
In the context of Myc, the absence of p73 allows increased maturation of...
(A) Semiquantitative RT-PCR analysis of p73 mRNA expression in sorted B220+CD19+ B cells isolated from spleens of p73–/–, nontransgenic WT and 4 week-old premalignant Eμ-myc mice. HPRT, control for equal cDNA input. (B) Proportion of cells in S-phase from total BM of 4-week-old nontransgenic (normal) and premalignant Eμ-myc mice of the indicated genotypes. Error bars represent SEM. (C) Cells isolated from spleens of 4-week-old nontransgenic (normal, n = 8 per genotype) and premalignant Eμ-myc mice (n = 8 per genotype) were stained with antibodies to B220 and IgM and analyzed by FACS. The percentage of B cells is indicated. Error bars represent SEM. (D) Cells isolated from BM and spleens of 4-week-old premalignant Eμ-myc mice of the indicated genotypes were stained with antibodies to B220, IgM, and IgD. Proportions of mature B cells (B220+IgM+), recirculating B cells (IgM+IgD+), and T1 transitional and marginal zone B cells (IgMhi/IgDlo) are shown. Error bars represent SEM. (E) BM and splenic cells from 3-week-old Eμ-myc mice of the indicated p53 and p73 genotypes were analyzed as in D. Error bars represent SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts